Recro Pharma (NASDAQ:REPH) Posts Quarterly Earnings Results, Beats Estimates By $0.29 EPS

Recro Pharma (NASDAQ:REPH) announced its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.29, Fidelity Earnings reports. The firm had revenue of $31.26 million for the quarter, compared to analyst estimates of $24.06 million. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 64.26%. Recro Pharma updated its FY 2019 guidance to EPS.

REPH traded up $0.05 on Friday, hitting $10.92. The company had a trading volume of 402,008 shares, compared to its average volume of 179,327. The company has a fifty day simple moving average of $9.98. Recro Pharma has a 12-month low of $5.49 and a 12-month high of $11.64.

In other Recro Pharma news, CEO Geraldine Henwood sold 144,806 shares of Recro Pharma stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $8.89, for a total value of $1,287,325.34. Following the transaction, the chief executive officer now owns 342,947 shares in the company, valued at $3,048,798.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arnaud Ajdler bought 40,000 shares of the business’s stock in a transaction on Friday, May 17th. The stock was bought at an average price of $9.00 per share, for a total transaction of $360,000.00. The disclosure for this purchase can be found here. 20.10% of the stock is owned by insiders.

Several brokerages have recently commented on REPH. ValuEngine upgraded Recro Pharma from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. Zacks Investment Research lowered Recro Pharma from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Recro Pharma presently has a consensus rating of “Buy” and a consensus price target of $11.30.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Earnings History for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with's FREE daily email newsletter.